Zobrazeno 1 - 10
of 253
pro vyhledávání: '"Chao H Huang"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The therapeutic landscape for patients with non-small cell lung cancer (NSCLC) has dramatically evolved with the development and adoption of immune checkpoint inhibitors (ICI) as front-line therapy. These novel antibodies target the interactions in i
Externí odkaz:
https://doaj.org/article/f32fadc168354053b6c78bbc6d031b5e
Autor:
Tahani Atieh, Chao H. Huang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
LCNEC of the lung comprises a small proportion of pulmonary malignancies. Traditionally, they have been classified based on histologic and immunohistochemistry characteristics with features of small cell and non-small cell lung cancer. The treatment
Externí odkaz:
https://doaj.org/article/aef1996b001f40dc882eae92539a4ae9
Autor:
J. Nicholas Bodor, Jyoti D. Patel, Heather A. Wakelee, Benjamin P. Levy, Hossein Borghaei, Bruna Pellini, Michael R. Costello, Jonathan E. Dowell, Gene Finley, Chao H Huang, Joel W. Neal, Jorge J Nieva, Sonam Puri, Mark A. Socinski, Christian Thomas, Eric A. Ross, Samuel Litwin, Margie L. Clapper, Joseph Treat
Publikováno v:
Clinical Lung Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da2fbf4307a7ba7d2b55051d07a1baaa
https://doi.org/10.1016/j.cllc.2023.05.003
https://doi.org/10.1016/j.cllc.2023.05.003
Autor:
Takefumi Komiya, Chao H. Huang
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Recent application of immunotherapy in clinical oncology revolutionized our management of advanced human cancers. Check point inhibitors targeting CTLA4 and PD-1/PD-L1 axis are immunotherapeutic agents currently available to treat a variety of cancer
Externí odkaz:
https://doaj.org/article/07997fea336746e0b1ce7a0bb62856e9
Autor:
Chao H Huang, Stephen K Williamson, Prakash eNeupane, Sarah A Taylor, Ace eAllen, Nora J Smart, Adelina M Uypeckcuat, Sarah eSpencer, Jo eWick, Holly eSmith, Peter J Van Veldhuizen, Karen eKelly
Publikováno v:
Frontiers in Oncology, Vol 5 (2016)
Background: Insulin-like growth factor 1 receptor (IGF-1R) regulates cell growth, proliferation and apoptosis. Adenocarcinoma and never-smokers have a higher expression of IGF-1R, which is associated with worse overall survival. Dalotuzumab-MK0646 (D
Externí odkaz:
https://doaj.org/article/d6ef07d5512e44d4ba18480f63ccc3f9
Autor:
Chao H. Huang, Benjamin C. Powers
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2012, Iss 6, Pp 137-147 (2012)
Externí odkaz:
https://doaj.org/article/98b1dfd87f97430880afc14f7ea045be
Autor:
Chao H Huang, Jo eWick, Gurusingham (Sitta) eSittampalam, Victor Sanjit eNirmalanandhan, Apar eGanti, Stephen K Williamson, Prakash C Neupane, Andrew eGodwin, Sarah eSchmitt, Nora J Smart, Sarah eSpencer, Peter J Van Veldhuizen
Publikováno v:
Frontiers in Oncology, Vol 4 (2014)
Abstract Background: SCLC, a variant of lung cancer marked by early metastases, accounts for 13% of all lung cancers diagnosed in US. Despite high response rates to treatment, it is an aggressive disease with a median survival of 9-11 months for pati
Externí odkaz:
https://doaj.org/article/c099dbe53c4d4a3896caacf2d951b043
Autor:
Chao H. Huang, John B. A. G. Haanen, Mehmet Altan, Faitg Thomas H, Brian H. Ladle, Adrian G. Sacher, Adam J. Schoenfeld, Taofeek K. Owonikoko, Dejka M. Araujo, Aisha N. Hasan, Sandra P. D'Angelo, Aiman Shalabi, Steven Attia, Jeffrey Yachnin, Brian A. Van Tine, David A. Liebner, Emily Butler, Jonathan Noujaim, Kai He
Publikováno v:
Journal of Clinical Oncology. 39:TPS2661-TPS2661
TPS2661 Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T-cell therapy using a genetically modified T-cell receptor (TCR) to improve recognition of cancer cells expressing NY-ESO-1/LAGE-1a. Next generation NY-ESO-1 TCR T-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8b9fdb3bd95581f082b633cf36a3fa3
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2661
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2661
Publikováno v:
Cancer Research. 79:777-777
Background: Lung cancer is the leading cause of cancer related death in the United States. Epidermal Growth Factor Receptor (EGFR) mutation predicts response to a tyrosine kinase inhibitor (TKI) of EGFR in approximately 25% of patients. Non-small cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3111777e762e73cde0537e6d065ebf85
https://doi.org/10.1158/1538-7445.am2019-777
https://doi.org/10.1158/1538-7445.am2019-777
Autor:
Emma Borrego-Diaz Reyes, Chao H. Huang, Andrew K. Godwin, Hannah Motes, Inamul Haque, Mukut Sharma
Publikováno v:
Cancer Research. 78:485-485
Objectives: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are now standard of care in lung cancer patients with EGFR mutation. Invariably, these patients develop resistance and require treatment with another EGFR-TKI or chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbab4465e863686c8eb29d4da15575c0
https://doi.org/10.1158/1538-7445.am2018-485
https://doi.org/10.1158/1538-7445.am2018-485